Glaxo to Pay $20 Million SEC Fine Over Bribery in China

Updated on
  • China fined pharmaceutical company $489 million for bribery
  • SEC says Glaxo had similar improper conduct in other countries

GlaxoSmithKline PLC agreed to pay $20 million to the U.S. Securities and Exchange Commission to settle allegations that a Chinese subsidiary of the pharmaceutical company bribed foreign officials to increase product sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.